M. Ekbal

Articles by M. Ekbal

Encouraging Improvement in Cytopenias of Patients With Myelodysplastic Syndromes With Thalidomide

ByA. Raza,L. Lisak,C. Anderews,L. Little,F. Zorat,V. Shetty,S. Alvi,S. Mundle,K. Allampallam,M. duRant,M. Ekbal,M. Muzammil

November 1st 2000

Myelodysplastic syndrome patients present with variable cytopenias even though their bone marrows are generally hypercellular. Excessive cytokine-induced apoptosis of hematopoietic cells in the marrows has been proposed as a possible

Latest Updated Articles

Encouraging Improvement in Cytopenias of Patients With Myelodysplastic Syndromes With Thalidomide
November 1st 2000

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Yoga Could Alter Cancer-Related Fatigue Levels Across Solid Tumors

Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC

109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)